HOUSING

ASTCT and EBMT have reserved rooms at a discounted rate at Eurostars Sitges Hotel. Information on how to make a hotel reservation will be distributed in the registration confirmation email.
Room Rate: 186.80€ Double room for Single Use/Night. Breakfast, VAT and local taxes included
TARGET AUDIENCE
The program is intended for both junior and senior members of the blood and marrow transplantation and cellular therapy field.
This conference is only for physicians and scientists who are currently practicing in the field of transplantation and cellular therapy and sponsoring companies. Please contact Yaiza Gonzalez if you are interested in participating as a sponsor.
REGISTRATION
Registration to this event is limited to a maximum of 120 total attendees. We are unable to accept additional registrants once the registration capacity has been met.
REGISTER
Type
|
Price
|
Junior Attendee Rate*
|
125€
|
Senior Attendee Rate
|
250€
|
*Junior attendees are defined as post doctoral fellows, current fellows, and junior faculty within the first three years of appointment.
PROGRAM AGENDA
Tuesday, May 23
Time |
Session |
9:00 - 9:15 AM |
Welcome and Introduction |
Immune Metabolism
Session Chair: Bruce Blazar, MD; University of Minnesota, US
|
9:15 - 9:45 AM |
Metabolic control of T cell differentiation in cancer
Greg Delgoffe, PhD; University of Pittsburgh, US |
9:45 - 10:15 AM |
Metabolic reprogramming of T cells to enhance GVL effects
Prof. Dr. Robert Zeiser; University of Freiburg, DE |
10:15 - 10:45 AM |
Obesity, inflammation and cancer
Jeffrey Rathmell, PhD; Vanderbilt University Medical Center, US |
10:45 - 10:55 AM |
Oral Abstract Presentation |
10:55 - 11:05 AM |
Oral Abstract Presentation |
11:05 - 11:15 AM |
Oral Abstract Presentation |
11:15 - 11:30 AM |
Break |
Graft vs Host Disease
Session Chair: Warren Schlomchik, MD; University of Pittsburgh, US
|
11:45 - 12:15 PM |
Target tissue: Tolerance and reminiscence
Pavan Reddy, MD; Baylor College of Medicine, US |
12:15 - 12:45 PM |
T-cell Exhaustion and GVHD/GVL
Takanori Teshima, MD; Hokkaido University Hospital, JP |
12:45 - 1:15 PM |
Anti-C19 CAR CD8 induced Tregs cell therapy to optimize GVHD/GVL outcome
Bruce Blazar, MD; University of Minnesota, US |
1:15 - 1:25 PM |
Oral Abstract Presentation |
1:25 - 1:35 PM |
Oral Abstract Presentation |
1:35 - 1:45 PM |
Oral Abstract Presentation |
1:45 - 5:30 PM |
Lunch + Afternoon Break |
5:30 - 6:30 PM |
Poster Tour + Networking Hour |
6:30 - 8:30 PM |
Keynote Lecture and Dinner
Megan Skyes, MD; Columbia University Medical Center, US
|
Wednesday, May 24
Time |
Session |
Stem Cell Biology
Session: Markus Manz, MD; University Hospital Zurich, CH
|
9:00 - 9:35 AM |
Harnessing the microenvironmental regulation for improved outcomes of HSCT
Markus Manz, MD; University Hospital Zurich, CH |
9:35 - 10:10 AM |
The microbiome-IL-1 axis drives HSC inflamm-aging and clonal hematopoiesis
Simón Méndez-Ferrer, PhD; University of Cambridge, UK
|
10:10 - 10:45 AM |
Non-genotoxic anti-CD117 antibody conditioning in hematopoietic stem cell transplantation
Judith Shizuru, MD; Stanford University, US |
10:45 - 11:00 AM |
Oral Abstract Presentation |
11:00 - 11:30 AM |
Break |
Cell Engineering
Session Chair: Chiara Bonini, MD; I.R.C.C.S Ospedale San Raffaele, IT
|
11:30 - 12:05 PM |
CAR T cells for brain tumors
Crystal Mackall, MD; Stanford University, US |
12:05 - 12:40 PM |
The UCL CAR T programme: Better Targets, Better Targeting
Claire Roddie, MD; University College London, UK
|
12:40 - 1:15 PM |
Modulating T cell memory and tumor glycosylation to improve CAR T cell therapy
Monica Casucci, PhD; I.R.C.C.S Ospedale San Raffaele, IT |
1:15 - 1:30 PM |
Oral Abstract Presentation |
1:30 - 5:30 PM |
Lunch + Afternoon Break |
5:30 - 6:30 PM |
Meet-the-Profession Session |
6:30 - 8:30 PM |
Keynote Lecture and Dinner
Luigi Naldini, MD, PhD; I.R.C.C.S Ospedale San Raffaele, IT |
Friday, May 25
Time |
Session |
Anti-Leukemic Strategies and NK Cells (Part I)
Session Chair: Nicolaus Kröger, MD; University Hospital Hamburg-Eppendorf, DE
|
9:00 - 9:30 AM |
Factors determining the transition from clonal hematopoiesis to myeloproliferative neoplasms and progression to myelofibrosis
Speaker: Prof. Dr. Radek Skoda; University Hospital Basel, CH |
9:30 - 10:00 AM |
Off-The-Shelf targeted NK cell therapies to treat leukemia
Jeffrey Miller, MD; University of Minnesota, US |
10:00 - 10:30 AM |
Effect of pre-leukemic mutations on hematopoietic stem cell and their progenies
Dominique Bonnet, PhD; Francis Crick Institute, UK |
10:30 - 11:00 AM |
TCR-T cell therapy for leukemia post-transplantation
Marie Bleakley, MD, PhD; Fred Hutchinson Cancer Center, US |
11:00 - 11:30 AM |
Break |
Anti-Leukemic Strategies and NK Cells (Part II)
Session Chair: Harry Dolstra, PhD; Radboud University Medical Centre, NL
|
11:30 - 12:00 PM |
Training NK cells for enhanced leukemia attack
Todd Fehniger, MD, PhD; Washington University School of Medicine, US |
12:00 - 12:30 PM |
Editing of T and HASC for improved CART function
John DiPersio, MD, PhD; Washington University School of Medicine, US |
12:30 - 12:40 PM |
Oral Abstract Presentation |
12:40 - 12:45 PM |
Closing Remarks |